USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Propranolol LA is a generic equivalent of Inderal LA
Topiramate is the generic version of Supernus Pharmaceuticals’ Trokendi XR
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Hospital joins with Intuitive to install da Vinci systems to support enhanced healthcare delivery and patient outcomes across India
Aims to build the largest connected healthcare ecosystem in India
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Subscribe To Our Newsletter & Stay Updated